TrkA is a binding partner of NPM‐ALK that promotes the survival of ALK + T‐cell lymphoma
Sign Up to like & getrecommendations! Published in 2017 at "Molecular Oncology"
DOI: 10.1002/1878-0261.12088
Abstract: Nucleophosmin‐anaplastic lymphoma kinase‐expressing (NPM‐ALK+) T‐cell lymphoma is an aggressive neoplasm that is more commonly seen in children and young adults. The pathogenesis of NPM‐ALK+ T‐cell lymphoma is not completely understood. Wild‐type ALK is a receptor… read more here.
Keywords: alk cell; alk; npm alk; cell ... See more keywords
EBP2, a novel NPM‐ALK‐interacting protein in the nucleolus, contributes to the proliferation of ALCL cells by regulating tumor suppressor p53
Sign Up to like & getrecommendations! Published in 2020 at "Molecular Oncology"
DOI: 10.1002/1878-0261.12822
Abstract: The oncogenic fusion protein nucleophosmin‐anaplastic lymphoma kinase (NPM‐ALK), found in anaplastic large‐cell lymphoma (ALCL), localizes to the cytosol, nucleoplasm, and nucleolus. However, the relationship between its localization and transforming activity remains unclear. We herein demonstrated… read more here.
Keywords: suppressor p53; alk; npm alk; tumor suppressor ... See more keywords
“Double hit” anaplastic large cell lymphoma with concurrent ALK and MYC rearrangements
Sign Up to like & getrecommendations! Published in 2020 at "American Journal of Hematology"
DOI: 10.1002/ajh.25980
Abstract: A 28-year-old man presented with a history of persistent left groin swelling for 2 years, which has shown slow growth in recent 2 months. He denied any B symptoms including fever, night sweats, and weight… read more here.
Keywords: lymphoma; double hit; image; alk ... See more keywords
Longitudinal monitoring by next‐generation sequencing of plasma cell‐free DNA in ALK rearranged NSCLC patients treated with ALK tyrosine kinase inhibitors
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.4663
Abstract: Patients with ALK‐rearranged non‐small cell lung cancer (ALK+ NSCLC) inevitably acquire resistance to ALK inhibitors. Longitudinal monitoring of cell‐free plasma DNA (cfDNA) next‐generation sequencing (NGS) could predict the response and resistance to tyrosine kinase inhibitor… read more here.
Keywords: cell; alk rearranged; cell free; next generation ... See more keywords
Differential Chemoproteomics Reveals MARK2/3 as Cell Migration‐Relevant Targets of the ALK Inhibitor Brigatinib
Sign Up to like & getrecommendations! Published in 2023 at "ChemBioChem"
DOI: 10.1002/cbic.202200766
Abstract: Metastasis poses a major challenge in cancer management, including EML4‐ALK‐rearranged non‐small cell lung cancer (NSCLC). As cell migration is a critical step during metastasis, we assessed the anti‐migratory activities of several clinical ALK inhibitors in… read more here.
Keywords: brigatinib; cell; eml4 alk; alk ... See more keywords
Targeted therapy for lung cancer: Beyond EGFR and ALK
Sign Up to like & getrecommendations! Published in 2023 at "Cancer"
DOI: 10.1002/cncr.34757
Abstract: Precision oncology comprises the set of strategies that aim to design the best cancer treatment based on tumor biology. A recognized subset of patients with non‐small cell lung cancer (NSCLC) harbor actionable genomic aberrations that… read more here.
Keywords: lung cancer; therapy lung; targeted therapy; alk ... See more keywords
Molecular investigation of ALK‐rearranged epithelioid fibrous histiocytomas identifies CLTC as a novel fusion partner and evidence of fusion‐independent transcription activation
Sign Up to like & getrecommendations! Published in 2022 at "Genes"
DOI: 10.1002/gcc.23038
Abstract: Epithelioid fibrous histiocytoma (EFH) is a rare cutaneous neoplasm, which is characterized by the presence of rearrangements involving the ALK gene. Although EFH was long considered a variant of fibrous histiocytoma, the identification of its… read more here.
Keywords: fusion partner; fusion; epithelioid fibrous; alk ... See more keywords
Evaluation of Lorlatinib Cerebrospinal Fluid Concentrations in Relation to Target Concentrations for Anaplastic Lymphoma Kinase (ALK) Inhibition
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Clinical Pharmacology"
DOI: 10.1002/jcph.2056
Abstract: Lorlatinib is a third‐generation, brain‐penetrant anaplastic lymphoma kinase (ALK) and c‐ros oncogene 1 (ROS1) tyrosine kinase inhibitor (TKI) with robust intracranial activity in patients with ALK‐ or ROS1‐positive non‐small cell lung cancer (NSCLC). Data from… read more here.
Keywords: lymphoma kinase; anaplastic lymphoma; kinase alk; kinase ... See more keywords
A novel fusion between CDC42BPB and ALK in a patient with quadruple wild-type gastrointestinal stromal tumor.
Sign Up to like & getrecommendations! Published in 2022 at "Molecular genetics & genomic medicine"
DOI: 10.1002/mgg3.1881
Abstract: BACKGROUND Gastrointestinal stromal tumors (GISTs) are the most common type of mesenchymal tumor in gastrointestinal tract, with striking features of morphology and immunohistochemistry. But GISTs in pregnancy could seldom be found. Pathogenic activating mutations of… read more here.
Keywords: fusion; novel fusion; cdc42bpb alk; alk ... See more keywords
Immunocytochemical Detection of ALK and ROS1 Rearrangements in Lung Cancer Cytological Samples.
Sign Up to like & getrecommendations! Published in 2021 at "Methods in molecular biology"
DOI: 10.1007/978-1-0716-1278-1_12
Abstract: The detection of molecular alterations such as ROS1 and ALK rearrangements is performed as part of the diagnosis of advanced-stage lung adenocarcinoma. These alterations allow the treatments with tyrosine kinase inhibitors. Cytological samples are very… read more here.
Keywords: detection; alk; cytological samples; alk ros1 ... See more keywords
Implementation of pharmacophore-based 3D QSAR model and scaffold analysis in order to excavate pristine ALK inhibitors
Sign Up to like & getrecommendations! Published in 2019 at "Medicinal Chemistry Research"
DOI: 10.1007/s00044-019-02410-9
Abstract: The utilisation of anaplastic lymphoma kinase (ALK) inhibitors has unveiled a magnificent clinical activity in ALK-positive non-small cell lung cancer (NSCLC), as well as against the sanctuary site of CNS in selected patients. However, the… read more here.
Keywords: alk inhibitors; order; alk; analysis ... See more keywords